bleomycin medac 15000 sv pulveris injekciju šķīduma pagatavošanai
medac gesellschaft für klinische spezialpräparate mbh, germany - bleomicīna sulfāts - pulveris injekciju šķīduma pagatavošanai - 15000 sv
bleomycin medac 30000 sv pulveris injekciju šķīduma pagatavošanai
medac gesellschaft für klinische spezialpräparate mbh, germany - bleomicīna sulfāts - pulveris injekciju šķīduma pagatavošanai - 30000 sv
maxitrol acu pilieni, suspensija
novartis pharma nv, belgium - dexamethasonum, neomycini sulfas, polymyxini b sulfas - acu pilieni, suspensija - 1 mg/3500sv/6000 sv/ml
polygynax mīkstās vaginālās kapsulas
laboratoire innotech international sas, france - neomycini sulphas, polymyxini b sulfas, nystatinum - mīkstās vaginālās kapsulas
polygynax mīkstās vaginālās kapsulas
laboratoire innotech international sas, france - neomycini sulphas, polymyxini b sulfas, nystatinum - vaginālā kapsula, mīkstā - 35000 sv/35000 sv/100000 sv
polygynax 35000 sv/35000 sv/100000 sv mīkstās vaginālās kapsulas
laboratoire innotech international sas, france - neomycini sulphas, polymyxini b sulfas, nystatinum - vaginālā kapsula, mīkstā - 35000 sv/35000 sv/100000 sv
polygynax mīkstās vaginālās kapsulas
laboratoire innotech international sas, france - neomycini sulphas, polymyxini b sulfas, nystatinum - vaginālā kapsula, mīkstā
vinblastine teva 1 mg/ml šķīdums injekcijām
teva pharma b.v., netherlands - vinblastīna sulfāts - Šķīdums injekcijām - 1 mg/ml
vincristine teva 1 mg/ml šķīdums injekcijām
teva pharma b.v., netherlands - vinkristīna sulfāts - Šķīdums injekcijām - 1 mg/ml
celdoxome pegylated liposomal
yes pharmaceutical development services gmbh - doksorubicīna hidrohlorīds - breast neoplasms; ovarian neoplasms; multiple myeloma; sarcoma, kaposi - antineoplastiski līdzekļi - celdoxome pegylated liposomal is indicated in adults:as monotherapy for patients with metastatic breast cancer, where there is an increased cardiac risk. or treatment of advanced ovarian cancer in women who have failed a first-line platinum-based chemotherapy regimen. in combination with bortezomib for the treatment of progressive multiple myeloma in patients who have received at least one prior therapy and who have already undergone or are unsuitable for bone marrow transplant. for treatment of aids-related kaposi’s sarcoma (ks) in patients with low cd4 counts (< 200 cd4 lymphocytes/mm3) and extensive mucocutaneous or visceral disease. celdoxome pegylated liposomal may be used as first-line systemic chemotherapy, or as second line chemotherapy in aids-ks patients with disease that has progressed with, or in patients intolerant to, prior combination systemic chemotherapy comprising at least two of the following agents: a vinca alkaloid, bleomycin and standard doxorubicin (or other anthracycline).